The BioNTech SE ADR BNTX shed 0.20% to $112.28 Friday, on what proved to be an all-around mixed trading session for the stock ...

Upon authorization by the European Commission, the Omicron KP.2-adapted COVID-19 vaccine will be available for individuals 6 months of age and ...

The latest, highly contagious subvariants are driving infections, but new vaccines may help stem the tide of another wave — ...

BioNTech has been boosted a wave of enthusiasm over another company’s cancer drug, which has turned the biopharma industry ...

On Thursday, Aug. 22, the United States Food and Drug Administration (FDA) approved and authorized updated versions of mRNA ...

It’s been over four years since the beginning of the COVID-19 pandemic. And since then, the virus has changed substantially.

Each household can receive up to four free tests from the site COVIDtest.gov. Once ordered, the at-home tests are mailed to ...

The BioNTech SE ADR BNTX slipped 7.29% to $115.62 Wednesday, on what proved to be an all-around rough trading session for the ...

Targeting the KP.2 strain is expected to provide better protection against COVID-19 based on current data. The 2024-2025 mRNA COVID-19 vaccines will include a monovalent component that corresponds to ...

The summer surge of COVID-19 has been decreasing in Sonoma County in early September, but the county’s health officer warns ...

The company reported Health Canada authorized the use of its Spikevax KP.2 shot for those aged six months and older. Last ...

Fintel reports that on September 17, 2024, Jefferies upgraded their outlook for BioNTech SE - Depositary Receipt () (NasdaqGS ...